Syngene FY26 profit drops 20% as biologics drags margins

What changed in Syngene’s FY26 results

Syngene International reported a weaker FY26 on profitability despite modest revenue growth, with management pointing to pressure from a single large biologics customer. Revenue from operations rose 3% year-on-year to ₹3,739 crore from ₹3,642 crore. But operating EBITDA declined 12% to ₹918 crore, compressing the operating EBITDA margin to 25% from 29% a year earlier. Profit after tax (PAT) before exceptional items fell to ₹380 crore, while reported PAT after exceptional items stood at ₹317 crore. The company said margins were also weighed down by additional operating costs, including those linked to a new biologics manufacturing facility in India coming into operations.

FY26 revenue grew, but EBITDA and margins fell

The full-year performance highlighted the gap between top-line stability and near-term cost and mix pressures. Revenue from operations increased by ₹97 crore year-on-year, but EBITDA fell by ₹125 crore, reflecting weaker operating leverage. The margin decline to 25% suggests the cost base grew faster than revenue during the year. Management commentary positioned the performance as being within revised full-year guidance, with the impact linked to one large-molecule biologics client rather than broad-based deterioration.

Q4 FY26: sequential improvement, but year-on-year pressure

The fourth quarter showed similar trends, even as sequential momentum improved. Q4 revenue rose 2% year-on-year to ₹1,037 crore and increased 13% quarter-on-quarter. Operating EBITDA in the quarter declined 12% year-on-year to ₹303 crore, and the EBITDA margin fell to 29% from 34% a year earlier. PAT before exceptional items in Q4 dropped 16% to ₹153 crore, while reported PAT after exceptional items was ₹148 crore. The quarter therefore continued to reflect margin pressure even with better sequential revenue movement.

Management explains the biologics client impact

Syngene’s Managing Director and CEO Peter Bains attributed the FY26 performance to the specific impact from a single large-molecule biologics client. He said full-year revenue from operations grew 3% and that the overall performance, including the 25% EBITDA margin, was in line with revised guidance. He also said the underlying business showed steady momentum outside the client-specific issue.

CFO highlights higher operating costs from new capacity

Chief Financial Officer Deepak Jain said margin pressure also reflected additional operating costs as Syngene brought a new biologics manufacturing facility in India into operations. Separate commentary around quarterly performance also flagged rising cost lines tied to new facilities, including higher power and utility expenses associated with new sites and increased depreciation in line with capacity additions.

Exceptional items: labour code costs and other one-offs

Exceptional items were a recurring factor in reported profitability. During the year, Syngene cited the impact of revised labour codes leading to higher gratuity liabilities, expenses related to employee termination benefits, and an insurance settlement. In Q3 FY26, the company recorded an exceptional loss of ₹76 crore due to changes in the labour code. It also reported additional gratuity costs of ₹65.8 crore on a standalone basis and ₹70.6 crore on a consolidated basis.

Q3 FY26: profit hit by exceptional charge and client-specific issue

In Q3 FY26, Syngene reported sharp pressure on profitability, driven by the ongoing impact related to a single commercial-stage product from its largest large-molecule biologics customer and the labour-code related exceptional charge. Consolidated net profit for the quarter decreased 88.6% year-on-year to ₹15 crore from ₹131.01 crore. Revenue from operations fell 2.8% year-on-year to ₹917 crore from ₹944 crore.

The market reaction was immediate. The stock fell as much as 5.7% to ₹559.10 on the NSE, the lowest level since April 5, 2023. Another market update noted the BSE-listed stock dipped 2.5% to ₹610 post-earnings.

Earlier quarters: Q1 growth, then a softer Q2

Syngene’s FY26 trajectory also showed uneven quarterly profitability. In Q1 FY26, revenue rose 11% year-on-year to ₹875 crore, EBITDA increased 19% to ₹206 crore with a 25% margin, and PAT grew 14% to ₹87 crore. In Q2 FY26, revenue from operations was ₹911 crore, up 2% year-on-year, while EBITDA declined 18% to ₹215 crore and PAT fell 37% year-on-year to ₹67 crore. The Q2 update cited factors such as an anticipated inventory correction in biologics manufacturing, a write-off of ₹27.7 crore for unrecoverable receivables, and a hedge loss of ₹11.8 crore.

Key numbers at a glance

Market impact and what investors tracked

The FY26 update reinforced two investor focus areas: client concentration risk and margin sensitivity during capacity ramp-ups. In Q3 FY26, management tied performance to a single biologics customer and, in another disclosure, pointed to an inventory correction linked to Librela (bedinvetmab), a monoclonal antibody used to treat osteoarthritis in dogs. The labour-code related provisions also added volatility to reported earnings, with a large exceptional loss in the quarter.

Stock moves reflected the uncertainty. Besides the intraday fall to ₹559.10 on the NSE after Q3 results, another update noted Syngene’s shares ended a day at ₹592.15 on the BSE, down 1.4%, while a separate post-earnings trade level was cited at ₹610 on the BSE after a 2.5% dip.

Why this matters for the CRDMO outlook

Syngene’s FY26 results show how a CRDMO can report steady revenue while profitability moves sharply due to mix, client-specific disruptions, and the timing of costs. The 400 basis point drop in full-year EBITDA margin to 25% highlights the combined effect of lower contribution from a key biologics relationship and higher operating costs tied to bringing new manufacturing infrastructure into operations. Exceptional items related to labour codes also underscore how regulatory changes can affect reported profits even when underlying demand remains intact.

Conclusion

Syngene ended FY26 with higher revenue but lower EBITDA and profit, and management attributed the pressure largely to a single large biologics customer and facility ramp-up costs. Investors are likely to track whether margins stabilise as the new biologics manufacturing capacity moves further into operations, and whether exceptional labour-code related impacts reduce in subsequent periods.